Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
about
Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active womenCervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinationsPrevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialDistribution of genital wart human papillomavirus genotypes in China: a multi-center study.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunityHuman papillomavirus vaccination: the population impact.Is administration of the HPV vaccine during pregnancy feasible in the future?Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.Meta-analysis of human papillomavirus infection concordance.Anal cancer treatment: current status and future perspectives.Human papillomavirus disease and vaccines in adolescents.Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis--an observational cohort study.Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.HPV - immune response to infection and vaccinationParadigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerUse of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey.Human papilloma virus vaccines: Current scenarioNext Generation Cancer Protection: The Bivalent HPV Vaccine for FemalesPopulation-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.A review of clinical trials of human papillomavirus prophylactic vaccines.Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewBurden of cervical, anal, and oral HPV in an inner-city pre-vaccine adolescent population.Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.Association Between Cumulative Psychosocial Risk and Cervical Human Papillomavirus Infection Among Female Adolescents in a Free Vaccination ProgramReview of Gardasil.Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected SubjectsImmunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosisProjected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United KingdomThe role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infectionTargeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.Does the HPV vaccination programme have implications for cervical screening programmes in the UK?HPV vaccines: state of the art.Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
P2860
Q26824062-31952D21-C8DD-4587-BC03-EE629CCFFF94Q28729883-B5657043-B636-44D8-8A25-AE240E3A7369Q30577846-3595DFE9-B391-4998-B4A3-7F7E78662FDEQ33626255-99A8CEA7-C8D4-465B-A1AA-1AB2EE4F6400Q33777098-CE1CD2DE-FA0C-4A9E-A7FB-610D28738AB0Q33791312-1DF85B14-7622-457A-B5AD-40E49450243EQ33797578-B49E73EE-0484-492D-8FD1-BEDC0E041979Q33806566-9C3933DC-5529-4F04-BD0C-D40B71B2A66CQ33920755-90FC679F-8A2C-4977-B1A8-38D94F29E79EQ33953881-F7487261-CC49-4768-AB0C-68F0A47EA597Q34210255-287409E9-C346-456E-A85E-329B35747617Q34293114-E3E9F6B8-48B8-47B3-AE3B-4FF27CB483F0Q34465769-D948FB9E-E7C2-4C20-B3D5-3B735AF21C8AQ34675079-A0D21E4D-7414-4CED-90AE-3729E913B1ADQ34802753-50823DB5-603E-48A8-88AA-0246490FAB2CQ34916304-0FEF0798-4113-4EAE-AC75-957BE4ED6A40Q34949073-CA424DB5-4367-4F86-AE37-EC0ACA6F6467Q35111092-AE0EE452-BF27-4F37-BB06-6A8536DE1DF8Q35180148-19B219FD-BF76-409B-A1F3-4F7E881BC802Q35258843-ECDBC618-5A88-4F95-98AA-0CE65270A13DQ35292968-1C15B2D7-1831-46A4-A5CA-16A0B836F4A7Q35366075-2CCBA687-9110-4005-84C4-28D4158C23C3Q35550810-AE3ADCC8-A3CB-469F-9F12-776F0442E87DQ35659008-DBB568B7-5DC0-427A-AA26-C8BE56665FECQ35812931-733F3404-3FFC-4146-BDEF-49744B906917Q36259403-D0B02ED5-F262-4673-8479-867BBA62839BQ36609068-85ADD6B6-9774-47C2-9D9B-8EB35EBC23BEQ36629357-CB45D7C3-062C-4292-A5F0-C4669BD184D8Q36888044-5B922B7A-D0DB-4642-8B91-CCCEBD57063AQ36904250-7C6808C2-34F9-4B44-B05E-8A44F80DAEECQ36949778-7E348B3E-4AEC-41DB-8CCB-3E5B67461617Q36977831-C655A4ED-F5B0-4FFF-B78D-2F97532A0A7CQ37221868-5B9C53E7-9E27-4BE6-BC96-AFB24F12EE4DQ37239410-7C1AAEEF-0AAB-44CE-9C4E-7EC1B874D91BQ37502417-F0C7F273-4EBC-48F3-8571-055C196D9ED0Q37668390-16B83BE9-8453-4B75-BDF8-884AEDF0890CQ37696770-02266A24-9C86-4E8B-AA8B-E21F381BC10AQ37709718-FA7426F6-A349-4A21-B4CC-727BEBF420C5Q37740000-90653B5A-904A-454A-BCE1-CC4E9ACF3A3FQ37798010-1AD8E3F4-38B4-4DC6-ADF8-4B47351CC67A
P2860
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@en
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@nl
type
label
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@en
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@nl
prefLabel
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@en
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@nl
P2093
P50
P356
P1433
P1476
Evaluation of quadrivalent HPV ...... or vaccine type HPV infection.
@en
P2093
Alfred Saah
Amha Tadesse
Daron G Ferris
Darron R Brown
Eliav Barr
Elmar A Joura
Eng Hseon Tay
Evan R Myers
F Xavier Bosch
Frank J Taddeo
P304
P356
10.4161/HV.5.10.9515
P577
2009-10-01T00:00:00Z